Last updated 2026-07-30
TL;DR
There's no documented CJC-1295 withdrawal syndrome in the medical literature, because CJC-1295 was never approved or formally trialed as a drug. What people report after stopping (fatigue, appetite changes, worse sleep) most likely reflects GH/IGF-1 levels returning to baseline, not a distinct withdrawal state. Taper isn't proven necessary, but stopping abruptly after months of use is where most anecdotal reports of a rough transition come from.
Does CJC-1295 cause withdrawal symptoms when you stop?
There's no peer-reviewed study documenting a withdrawal syndrome from CJC-1295, and that's mostly because CJC-1295 itself was never taken through the kind of long-term human trials that would let researchers characterize one. What exists is a small body of pharmacokinetic and pharmacodynamic work on the parent compound, modified GRF(1-29), plus a much larger body of research on growth hormone-releasing hormone (GHRH) physiology generally [1]. What people report anecdotally after stopping, tiredness, appetite swings, flatter mood, worse sleep for a week or two, is plausible given how the GH axis works, but it isn't the same thing as a documented withdrawal syndrome like you'd see with opioids or benzodiazepines. There's no rebound hyperprolactinemia, no seizure risk, no physical dependence mechanism described anywhere in the endocrine literature for GHRH analogues. The honest answer is: symptoms some people feel are consistent with GH/IGF-1 dropping back to your personal baseline, not a drug-specific withdrawal state. If you want the base rate for how the compound performs in the studies that do exist, cjc-1295 reviews rounds up what's actually been measured versus what's forum lore.
What happens to your GH and IGF-1 levels after you stop?
GH and IGF-1 should return toward your pre-treatment baseline once the analogue clears your system and the pulsatile GH release it was stimulating stops. The timeline for that depends entirely on which version of CJC-1295 you're talking about, because the two forms behave completely differently in the body. CJC-1295 without DAC (also sold as Mod GRF 1-29) has a short circulating half-life, commonly cited around 30 minutes in the injected, unmodified GRF fragment literature it's derived from [2]. Practically, that means GH pulses it triggers are over within hours, and by a day or two after your last dose, there's essentially none of the peptide left acting on your pituitary. CJC-1295 with DAC (Drug Affinity Complex) binds serum albumin and was measured with an elimination half-life of about 6.5 days in the original pharmacology paper by Teichman and colleagues [3], with sustained elevation of GH and IGF-1 over multi-day dosing intervals in that same study. That means after stopping DAC-containing CJC-1295, meaningful drug activity can linger for two to three weeks before it's fully cleared, and IGF-1 levels drift down gradually over that window rather than dropping off a cliff. So 'stopping' isn't a single event with DAC. Your last injection keeps doing something for days afterward. That's the core practical difference to understand before you decide how, or whether, to taper.
CJC-1295 with DAC vs without DAC: does the difference matter for stopping?
| Approx. half-life | ~30 minutes [2] | ~6.5 days [3] | |
|---|---|---|---|
| GH pulse pattern | Sharp, short pulse per dose | Sustained elevation across days | |
| Typical dosing frequency (studied/reported) | Multiple times daily | Once every 1-2 weeks in the Teichman study [3] | |
| Drug clearance after last dose | Effectively gone within ~24-48 hours | Detectable effect for 2-3+ weeks | |
| Practical stopping experience | Fast return to baseline pulsatility | Slower, more gradual decline in GH/IGF-1 | Because the no-DAC version clears fast, stopping it is pharmacologically simple: your next natural GH pulse pattern reasserts itself within a day or two. The DAC version is the one where people are more likely to notice a slower fade, simply because the drug is still bound to albumin and still nudging the pituitary for a couple of weeks after the last shot. If you're deciding between the two before you even start, cjc-1295 pros and cons covers the tradeoffs in more depth, including why some users deliberately avoid DAC because of that longer tail. |
Yes, and it's the single most important variable in this whole topic. The two forms are frequently sold under the same generic name, which causes a lot of confusion in sourcing and in stopping protocols. | Feature | CJC-1295 without DAC | CJC-1295 with DAC |
Is a taper necessary, or can you just stop?
No clinical guidance exists that mandates a taper for CJC-1295, because no regulatory body has approved it as a drug with an established discontinuation protocol. The FDA has explicitly flagged CJC-1295 as a substance that compounding pharmacies should not use, placing it on a list of bulk drug substances with safety concerns tied to unknown long-term effects and inadequate characterization [4]. That regulatory gap means there's no official taper schedule to point to, because there's no official use pattern to begin with. With that caveat: a lot of clinicians who work with GH secretagogues off-label extrapolate from general endocrine principle rather than CJC-1295-specific data. The pituitary-GH axis has feedback loops, and abrupt cessation of most things that stimulate a system tends to be tolerated fine physiologically, if not always comfortably subjectively. There's no evidence of a rebound surge or crash analogous to corticosteroid withdrawal. Practically, if someone has been running the no-DAC version, stopping cold has almost no pharmacokinetic consequence, since the drug is gone within a day regardless. For the DAC version, a 'taper' in the literal sense (progressively smaller doses) hasn't been studied, but simply spacing out the last one or two doses further apart accomplishes something similar to a taper, since the long half-life already smooths the decline. Whether that extra step is worth it is a judgment call, not something backed by trial data.
What symptoms do people actually report after stopping?
The reports clustering across anecdotal sources (forums, peptide-community write-ups, not clinical registries) tend to be: reduced sleep quality, lower energy, appetite changes, and a subjective sense of 'flatness' in the weeks after stopping. None of these have been measured in a controlled study specific to CJC-1295 cessation, so treat this section as a description of folklore, clearly labeled as such, not evidence. What's biologically plausible: GH has well-documented effects on sleep architecture, particularly slow-wave sleep, through its interaction with the GH/IGF-1 axis, and that relationship is described in sleep medicine literature independent of any peptide product [1]. If GH pulses were elevated during use and drop back to baseline after stopping, a temporary dip in perceived sleep quality is a reasonable expectation, not a surprising one. Appetite changes are similarly plausible given that ghrelin-mimetic compounds like ipamorelin (often stacked with CJC-1295) directly stimulate hunger through the ghrelin receptor, and that mechanism is well-characterized in the endocrinology literature on GH secretagogues [5]. Stopping ipamorelin specifically, more than stopping CJC-1295 itself, is probably what drives appetite-related reports in people running the common combination. For a broader sense of what's actually documented across the full course of use, more than the stopping phase, cjc-1295 results timeline walks through what's measured at each stage.
Does stopping CJC-1295 cause a 'crash' like some anabolic compounds?
Not in the way that term gets used for anabolic-androgenic steroids, where suppressed endogenous testosterone production creates a well-documented hormonal trough after stopping. CJC-1295 works through a different mechanism entirely: it's a GHRH analogue that stimulates your own pituitary to release GH, rather than replacing a hormone your body would otherwise stop making on its own. There's no equivalent of hypothalamic-pituitary-gonadal axis suppression described for GHRH analogues in the literature. The pituitary somatotrophs that release GH aren't shut down by CJC-1295 use the way the HPG axis can be suppressed by exogenous testosterone. That's a mechanistic reason to expect a gentler stop, even though it isn't the same as having a trial that measured it directly. The closest thing to a 'crash' anyone is likely to notice is IGF-1 and GH readings coming back down to whatever they were before you started, over the days-to-weeks window discussed above depending on DAC vs non-DAC. If your baseline GH production was already low before you started (which is common with age-related decline), returning to that baseline might feel like a step down, purely because you'd gotten used to higher levels, not because anything pathological is happening.
How long do the effects of CJC-1295 last after your last dose?
For the no-DAC form, meaningful pharmacological activity is over within roughly 24 to 48 hours of the last injection, consistent with its short half-life [2]. Any benefits attributed to the daily GH pulse (recovery, sleep quality) would be expected to fade on a similar timescale, though again, this is inference from pharmacokinetics, not a study that measured post-cessation outcomes directly. For CJC-1295 with DAC, the 6.5-day half-life described in the Teichman study means roughly four to five half-lives, about 26 to 33 days, before the drug is essentially fully cleared from circulation [3]. IGF-1 elevations in that same study were sustained across a 6-day dosing interval, which tells you the effect doesn't disappear the moment you skip a dose; it fades gradually. Downstream effects like changes in body composition or skin quality that built up over months of use don't reverse on the same timeline as the drug clearing. Those are slower physiological changes, and if they occurred, they'd be expected to regress slowly too, over weeks to months, independent of how fast the peptide itself leaves your bloodstream.
Do you need to stop ipamorelin at the same time as CJC-1295?
There's no requirement to stop them together, but most people using the combination do stop both at once since they're typically dosed in the same injection or same routine. The rationale for pairing them in the first place is mechanistic: CJC-1295 works through the GHRH receptor while ipamorelin works through the ghrelin receptor (also called the GH secretagogue receptor), and animal and in vitro work on combining a GHRH analogue with a ghrelin-receptor agonist has shown a synergistic-style additive effect on GH release compared to either compound alone [6]. That's the theory. It has not been demonstrated as a settled clinical outcome in humans with long-term safety and efficacy data; it's an extrapolation from receptor pharmacology and older combination studies with other GHRH/GHRP pairs. Because ipamorelin has its own short half-life, generally cited in the range of about 2 hours in the pharmacology literature on the compound [7], stopping it has a fast pharmacokinetic resolution similar to no-DAC CJC-1295. If someone is running CJC-1295 with DAC alongside ipamorelin, the ipamorelin effect fades quickly while the CJC-1295 with DAC effect lingers for weeks, so the two don't necessarily taper off in sync even if you stop both on the same day. If you're weighing whether the combination is worth the cost and complexity versus running either alone, is cjc-1295 worth it and cjc-1295 success rate both address that question directly.
Can you restart CJC-1295 after stopping, and does cycling matter?
People commonly cycle GH secretagogues, running a course for a number of weeks, stopping, then restarting later, but there's no clinical trial establishing an optimal on/off schedule for CJC-1295 specifically. The idea behind cycling, often borrowed from bodybuilding culture rather than endocrinology, is to prevent pituitary desensitization from constant stimulation, but there's limited direct evidence quantifying whether or how much desensitization actually occurs with this specific analogue over the timeframes people typically use it. What is documented: continuous, non-pulsatile GHRH exposure can lead to reduced pituitary responsiveness over time in general endocrine physiology, which is part of why the body's natural GH release is pulsatile in the first place rather than constant [1]. That's a reasonable theoretical basis for why some protocols favor cycling or at least dosing patterns that mimic natural pulsatility rather than continuous exposure. It is not the same as having a study that measured CJC-1295 receptor desensitization directly in humans over months of use. Restarting after a break appears, based on the mechanism, to simply pick back up where you left off pharmacologically, since there's no described accumulation of resistance or tolerance specific to this compound in the literature. Whether restarting produces the same subjective effects as the first course is not something anyone has measured.
Is there a medical reason to stop CJC-1295 immediately?
Yes, several, and these apply regardless of which form you're using. Stop and contact a clinician if you notice signs of acromegaly-like changes (increasing shoe or ring size, jaw or brow growth, joint pain), because sustained IGF-1 elevation from any GH secretagogue carries that theoretical risk, and it's the same category of concern regulators cite when discussing unsupervised GH-axis stimulation [4]. Stop if you develop new or worsening headaches with visual changes, which could indicate pituitary or intracranial issues that need evaluation, not self-management. Stop if you have a personal or strong family history of cancer, since IGF-1 signaling is implicated in some tumor growth pathways, and this is part of why the FDA's concern list treats CJC-1295 as a substance needing more safety characterization rather than a benign wellness product [4]. Stop if you notice significant injection site reactions, swelling, or signs of infection that don't resolve. And stop, straightforwardly, if lab work shows IGF-1 climbing well outside the normal reference range for your age and sex; that's a concrete, measurable reason to pause and get bloodwork repeated, rather than pushing through based on how you feel subjectively.
What should you actually do before you stop, and where does sourcing fit in?
Get baseline labs before you start (IGF-1 at minimum) so that if you ever wonder whether your levels are returning to normal after stopping, you have a real number to compare against instead of guessing. This is the single most useful practical step, and it costs far less than months of the peptide itself. If you're working with a provider who prescribes and monitors this off-label, ask them directly what their stopping protocol is and why, since practices vary and the honest answer from most competent clinicians will acknowledge the limited evidence base rather than pretend there's a settled protocol. CJC-1295 Co works from a provider-reviewed model that connects people to that kind of oversight and to a fulfilling pharmacy partner, rather than leaving dosing and discontinuation decisions to forum consensus. Don't stop and restart repeatedly based on how you feel day to day; that's the pattern most likely to produce confusing, hard-to-interpret subjective swings that have nothing to do with the drug's actual pharmacokinetics. If you want a wider view of what outcomes look like across a full course before you get to the stopping question, cjc-1295 before and after is the companion piece worth reading alongside this one.
Frequently asked questions
Does CJC-1295 have withdrawal symptoms like a controlled substance?
No. There's no documented withdrawal syndrome, physical dependence mechanism, or rebound effect described in the endocrine literature for CJC-1295. It's not a controlled substance and doesn't work through the receptor systems (like opioid or GABA receptors) that cause classic withdrawal. Reported post-stopping symptoms are more consistent with GH/IGF-1 returning to baseline than true withdrawal.
How long does it take for CJC-1295 to leave your system?
The no-DAC form clears in roughly 24 to 48 hours given its short half-life, cited around 30 minutes for the parent GRF fragment [2]. CJC-1295 with DAC has an elimination half-life of about 6.5 days [3], so it takes roughly 4 to 5 half-lives, about 26 to 33 days, to fully clear.
Do you need to taper off CJC-1295?
There's no clinical protocol requiring a taper. For the no-DAC version, tapering has minimal pharmacokinetic benefit since the drug clears within a day or two regardless. For CJC-1295 with DAC, its long half-life already produces a gradual decline naturally, which functions similarly to a taper even without one being explicitly scheduled.
What's the difference between CJC-1295 with DAC and without DAC for stopping purposes?
No-DAC CJC-1295 has roughly a 30-minute half-life and clears within a day or two of stopping. CJC-1295 with DAC binds albumin and has a roughly 6.5-day half-life [3], meaning effects and detectable drug activity linger for two to three weeks after the last dose, so stopping is a slower process.
Will your GH levels crash after stopping CJC-1295?
There's no documented crash mechanism like the hormonal suppression seen with anabolic steroids. CJC-1295 stimulates your own pituitary rather than replacing a hormone your body stops producing, and no HPG-axis-style suppression is described for GHRH analogues. GH and IGF-1 are expected to return gradually to your personal baseline, not drop suddenly.
Can stopping CJC-1295 affect your sleep?
It's plausible. GH influences slow-wave sleep architecture through well-documented mechanisms in sleep medicine literature [5]. If GH pulses were elevated during use, a temporary dip in perceived sleep quality after stopping is reasonable to expect, though no study has measured this specifically for CJC-1295 cessation.
Is it safe to stop CJC-1295 cold turkey?
Nothing in the available pharmacology suggests a medical need to taper. For no-DAC CJC-1295, the drug is gone within about a day or two regardless of how you stop. For DAC-containing CJC-1295, its long half-life already creates a natural gradual decline. No abrupt-cessation risk has been documented in the literature.
Does stopping ipamorelin at the same time as CJC-1295 matter?
Most people stop both together since they're usually injected together, but there's no requirement to. Ipamorelin has a short half-life, around 2 hours in pharmacology literature [8], so it clears fast regardless. If paired with CJC-1295 with DAC, the ipamorelin effect fades quickly while the CJC-1295 effect lingers for weeks.
Why isn't CJC-1295 FDA approved, and does that affect stopping guidance?
CJC-1295 is on the FDA's list of bulk drug substances that compounding pharmacies should not use, due to safety concerns and inadequate characterization [4]. Because it was never approved as a drug, there's no official prescribing information or discontinuation protocol, which is why stopping guidance relies on general endocrine principle rather than a labeled taper schedule.
Can you develop tolerance to CJC-1295 that affects stopping?
Continuous non-pulsatile GHRH stimulation can reduce pituitary responsiveness in general endocrine physiology [1], which is the theoretical basis some cycling protocols use. But no study has directly measured tolerance or desensitization specific to CJC-1295 over realistic use periods, so this remains a plausible mechanism rather than a proven outcome.
What symptoms mean you should stop CJC-1295 immediately, more than at the end of a planned course?
Stop right away for signs of acromegaly-like changes (jaw, hand, or foot growth), new headaches with vision changes, unresolved injection site reactions, or IGF-1 levels well outside your normal reference range on bloodwork. These warrant a clinician visit before restarting anything, given the theoretical cancer-signaling concerns tied to elevated IGF-1 [4].
Does stopping CJC-1295 reverse body composition changes?
If changes occurred, they'd be expected to regress slowly over weeks to months, independent of how fast the peptide clears from your blood. This hasn't been measured in a controlled study specific to CJC-1295 discontinuation, so treat any timeline here as inference from general physiology, not established data.
Sources
- NIH StatPearls, Physiology of Growth Hormone: GH release is pulsatile and regulated by hypothalamic feedback; continuous GHRH stimulation can reduce pituitary responsiveness
- NIH PubChem, Sermorelin/GRF(1-29) pharmacology summary: Unmodified GRF(1-29) fragment has a short circulating half-life, around 30 minutes
- Teichman SL, et al., Journal of Clinical Endocrinology & Metabolism (2006): CJC-1295 with DAC has an elimination half-life of approximately 6.5 days and sustains GH/IGF-1 elevation over multi-day dosing
- U.S. FDA, Bulk Drug Substances Nominated for the 503A Bulks List (CJC-1295 safety review): FDA has flagged CJC-1295 as a substance not recommended for compounding due to safety concerns and inadequate characterization
- NIH PubChem, Ghrelin receptor (GHS-R) pharmacology: Ghrelin receptor agonists like ipamorelin stimulate appetite through the GH secretagogue receptor pathway
- Sigalos JT, Pastuszak AW, Sexual Medicine Reviews (2018), GH-releasing peptide combination pharmacology: Combining a GHRH analogue with a ghrelin-receptor agonist produces additive GH release compared to either compound alone
- NIH PubChem, Ipamorelin compound summary: Ipamorelin has a short half-life, cited around 2 hours in pharmacology literature